Edwards Lifesciences Corporation (NYSE:EW) CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $115.99, for a total value of $3,816,071.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Michael A. Mussallem also recently made the following trade(s):

  • On Monday, July 31st, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00.
  • On Wednesday, June 7th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $118.05, for a total value of $3,883,845.00.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 1.83% during mid-day trading on Thursday, hitting $114.13. The company had a trading volume of 981,986 shares. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a 50-day moving average price of $117.20 and a 200-day moving average price of $105.15. The firm has a market capitalization of $24.10 billion, a PE ratio of 34.62 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.76 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/10/michael-a-mussallem-sells-32900-shares-of-edwards-lifesciences-corporation-nyseew-stock.html.

Several equities research analysts have recently weighed in on EW shares. Vetr cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 price target for the company. in a research note on Monday, May 15th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price target for the company in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) started coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price target for the company. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, SunTrust Banks, Inc. increased their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $121.13.

Several institutional investors have recently added to or reduced their stakes in the stock. Beese Fulmer Investment Management Inc. boosted its position in Edwards Lifesciences Corporation by 9.9% in the first quarter. Beese Fulmer Investment Management Inc. now owns 28,412 shares of the medical research company’s stock valued at $2,672,000 after buying an additional 2,555 shares during the last quarter. Cim LLC purchased a new position in Edwards Lifesciences Corporation during the first quarter valued at $7,886,000. American Research & Management Co. boosted its position in Edwards Lifesciences Corporation by 6.6% in the first quarter. American Research & Management Co. now owns 7,010 shares of the medical research company’s stock valued at $659,000 after buying an additional 435 shares during the last quarter. Torch Wealth Management LLC purchased a new position in Edwards Lifesciences Corporation during the first quarter valued at $1,635,000. Finally, Fox Run Management L.L.C. purchased a new position in Edwards Lifesciences Corporation during the first quarter valued at $1,383,000. 84.15% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.